Detection of Occult Disease in Breast Cancer Using Fluorodeoxyglucose Camera-Based Positron Emission Tomography

This publication has 17 references indexed in Scilit:

• 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
  Journal of Clinical Oncology, 2001
• Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies
  European Journal of Nuclear Medicine and Molecular Imaging, 1999
• British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United Kingdom
  European Journal of Surgical Oncology, 1999
• Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.
  Radiology, 1998
• PET in oncology: Will it replace the other modalities?
  Seminars in Nuclear Medicine, 1997
• Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer Patients
  JAMA, 1994
• Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
  Radiology, 1993
• CA 15-3 in patients with locoregional and metastatic breast carcinoma
  Cancer, 1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
  The Lancet, 1992
• Positron-Emission Tomographic Scanning of Primary and Metastatic Breast Carcinoma with the Radiolabeled Glucose Analogue 2-Deoxy-2-[¹⁸F]Fluoro-d-Glucose
  New England Journal of Medicine, 1991